Monday, January 06, 2020 9:32:53 PM
DMOST....."In Like Flint", look towards a huge pay day down the road, in a relatively short time frame.
Are Options Traders Betting on a Big Move in Savara (SVRA) Stock?
Investors in Savara Inc. SVRA need to pay close attention to the stock based on moves in the options market lately. That is because the Jan 17, 2020 $5.00 Call had some of the highest implied volatility of all equity options today.
What is Implied Volatility?
Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.
What do the Analysts Think?
Clearly, options traders are pricing in a big move for Savara shares, but what is the fundamental picture for the company? Currently, Savara is a Zacks Rank #3 (Hold) in the Medical - Drugs industry that ranks in the Top 23% of our Zacks Industry Rank. Over the last 30 days, one analyst has increased the earnings estimate for the current quarter, while none have dropped their estimates. The net effect has narrowed our Zacks Consensus Estimate for the current quarter from a loss of 52 cents per share to a loss of 49 cents in that period.
Given the way analysts feel about Savara right now, this huge implied volatility could mean there’s a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.
https://finance.yahoo.com/news/options-traders-betting-big-move-143002217.html
GO SVRA
"PEACE"
Are Options Traders Betting on a Big Move in Savara (SVRA) Stock?
Investors in Savara Inc. SVRA need to pay close attention to the stock based on moves in the options market lately. That is because the Jan 17, 2020 $5.00 Call had some of the highest implied volatility of all equity options today.
What is Implied Volatility?
Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.
What do the Analysts Think?
Clearly, options traders are pricing in a big move for Savara shares, but what is the fundamental picture for the company? Currently, Savara is a Zacks Rank #3 (Hold) in the Medical - Drugs industry that ranks in the Top 23% of our Zacks Industry Rank. Over the last 30 days, one analyst has increased the earnings estimate for the current quarter, while none have dropped their estimates. The net effect has narrowed our Zacks Consensus Estimate for the current quarter from a loss of 52 cents per share to a loss of 49 cents in that period.
Given the way analysts feel about Savara right now, this huge implied volatility could mean there’s a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.
https://finance.yahoo.com/news/options-traders-betting-big-move-143002217.html
GO SVRA
"PEACE"
Recent SVRA News
- Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026 • Business Wire • 05/20/2026 12:15:00 PM
- Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) • Business Wire • 05/19/2026 06:15:00 PM
- Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) • Business Wire • 05/18/2026 06:55:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/12/2026 08:05:39 PM
- Savara Reports First Quarter Financial Results and Provides Business Update • Business Wire • 05/12/2026 08:05:00 PM
- Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference • Business Wire • 05/11/2026 08:05:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/24/2026 08:26:53 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/24/2026 08:24:46 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/24/2026 08:22:42 PM
- Savara Announces New Employment Inducement Grant • Business Wire • 04/17/2026 08:05:00 PM
- Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) • Business Wire • 04/15/2026 08:05:00 PM
- Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference • Business Wire • 04/14/2026 12:05:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/10/2026 08:18:47 PM
- Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) • Business Wire • 04/07/2026 12:05:00 PM
- Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) • Business Wire • 03/30/2026 12:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 08:16:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/13/2026 12:30:15 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/13/2026 12:10:55 PM
- Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update • Business Wire • 03/13/2026 12:05:00 PM
- Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) • Business Wire • 03/06/2026 09:05:00 PM
- Savara Announces Participation in 2026 Citizens Life Sciences Conference • Business Wire • 03/04/2026 09:05:00 PM
- Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) • Business Wire • 02/20/2026 09:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2026 10:30:13 PM
